Monitoring among patients at risk for metabolic syndrome secondary to concomitant antiretroviral and second-generation antipsychotic therapy in an HIV patient population

Nasar Ansari, Divya Akula, Kelly Murray, John Bury, Christina Connel

Research output: Contribution to conferencePoster

Abstract

Purpose: Second-generation antipsychotics (SGAs) and protease inhibitors (PIs) have significant metabolic side effect profiles. These risks are compounded with concomitant therapy, both due to additive side effects and as a result of the interaction between the classes which can increase serum SGA concentrations. The goal of this study is to explore the prevalence of metabolic syndrome among patients on concurrent SGA and PI therapy compared to SGA use with other antiretroviral therapy (ART) and to evaluate current risk management practices.

Introduction to Methods: This study has been approved by the Institutional Review Board. Monitoring, incidence of metabolic syndrome, and dosage adjustments among patients taking both SGAs and PIs will be compared to those on concomitant SGA and either integrase inhibitor or non-nucleoside reverse transcriptase inhibitor therapy. A retrospective review of a randomized selection of 100 charts of patients taking both SGAs and ART from September 1, 2017 to September 1, 2018 will be conducted. Monitoring frequency and parameters will be compared to that recommended by the American Diabetes Association for individuals taking SGAs. Our goal is to determine the prevalence of patients at risk for the potential long-term consequences of SGA and PI combination therapy compared to other ART and to evaluate current clinical monitoring and preventative strategies that are in place.
Original languageAmerican English
StatePublished - 22 Aug 2020
EventOklahoma State University Center for Health Sciences Research Day 2019 - Oklahoma State University Center for Health Sciences, TULSA, United States
Duration: 21 Feb 201922 Feb 2019
https://hdl.handle.net/11244/323882

Conference

ConferenceOklahoma State University Center for Health Sciences Research Day 2019
Abbreviated titleResearch Day 2019
CountryUnited States
CityTULSA
Period21/02/1922/02/19
Internet address

Fingerprint Dive into the research topics of 'Monitoring among patients at risk for metabolic syndrome secondary to concomitant antiretroviral and second-generation antipsychotic therapy in an HIV patient population'. Together they form a unique fingerprint.

Cite this